Krystexxa (pegloticase) / Amgen 
Welcome,         Profile    Billing    Logout  
 16 Diseases   4 Trials   4 Trials   584 News 


1234567»
  • ||||||||||  Review, Journal:  An update on the pharmacotherapy of gout. (Pubmed Central) -  Jan 3, 2025   
    There are also emerging therapies in development. However, there is increasing personalization of treatment, adjusting pharmacotherapy depending on comorbidities, such as chronic kidney disease and ischemic heart disease, as well as patient preference.
  • ||||||||||  Krystexxa (pegloticase) / Amgen
    GFR Recovery in a Patient with Stage 4 CKD and Chronic Uncontrolled Gout after Treatment with Intravenous (IV) Pegloticase () -  Oct 12, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_5494;    
    The findings of his case proposes that treatment with pegloticase IV could be beneficial for patients with uncontrolled gout in terms of eGFR recovery and also reduction in CKD progression by stabilizing chronic uncontrolled gout. Potentially this may leed to future controlled trials which may further evaluate pegloticase as a treatment for GFR recovery and GFR protection in patients with CKD and chronic gout..
  • ||||||||||  Krystexxa (pegloticase) / Amgen
    Dual-Energy CT Bone Findings in Kidney Transplant Recipients with Uncontrolled Gout (Exhibit Hall, Convention Center) -  Sep 23, 2024 - Abstract #KIDNEYWEEK2024KIDNEY_WEEK_2519;    
    Though not an intended PROTECT outcome, DECT showed overall poor bone health. Given additional erosive bone/joint damage MSU deposits can cause, findings suggest effective gout management as an opportunity to improve an aspect of bone health in KTRs with gout.Reference1.
  • ||||||||||  Krystexxa (pegloticase) / Amgen
    Journal:  Controversies and practical management of patients with gout and chronic kidney disease. (Pubmed Central) -  Sep 21, 2024   
    We believe that kidney specialists should consider gout as a major complication of CKD and actively manage it in their patients. Here, we present insights from nephrologists and rheumatologists on a team approach to gout management that includes the nephrologist.
  • ||||||||||  Krystexxa (pegloticase) / Amgen
    PATIENT-REPORTED QUALITY OF LIFE IN UNCONTROLLED GOUT AND CHANGES WITH INTENSIVE URATE-LOWERING: COMPARISON OF TOPHACEOUS AND NON-TOPHACEOUS PATIENTS () -  May 29, 2024 - Abstract #EULAR2024EULAR_2979;    
    However, full QOL improvements took longer in patients with tophi, presumably due to their higher urate burden at baseline. Prior publications have established that 52 weeks of pegloticase treatment results in near-total depletion of deposited urate.[6,7] Therefore, the current findings clinically support the known association between tophi and quality of life impact,[1,2] also suggesting that tophaceous gout patients in particular may benefit from a longer pegloticase treatment course.
  • ||||||||||  Krystexxa (pegloticase) / Amgen
    INFLUENCE OF ACUTE GOUT FLARE AND SERUM URATE LOWERING ON BIOMARKERS OF SYSTEMIC INFLAMMATION () -  May 29, 2024 - Abstract #EULAR2024EULAR_2974;    
    With prolonged SU-lowering, subsequent deposited urate depletion,[11,12] and flare cessation, transient increases in hsCRP and IL-6 were no longer observed and mean biomarker levels remained at/slightly below pre-treatment values. Of note, biomarker levels were highly variable between patients and further study is needed to confirm a relationship between gout flares and inflammatory biomarker levels.
  • ||||||||||  Krystexxa (pegloticase) / Amgen
    Enrollment open, Trial completion date, Trial primary completion date:  Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome (clinicaltrials.gov) -  May 27, 2024   
    P4,  N=10, Recruiting, 
    Of note, biomarker levels were highly variable between patients and further study is needed to confirm a relationship between gout flares and inflammatory biomarker levels. Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025 | Active, not recruiting --> Recruiting
  • ||||||||||  Krystexxa (pegloticase) / Amgen
    Trial primary completion date:  A Phase 4, Open-label Study of KRYSTEXXA (clinicaltrials.gov) -  Apr 30, 2024   
    P4,  N=50, Completed, 
    Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025 | Active, not recruiting --> Recruiting Trial primary completion date: Oct 2023 --> May 2023
  • ||||||||||  Krystexxa (pegloticase) / Amgen, Rituxan (rituximab) / Roche
    Enrollment open:  Recapturing Immune Tolerance to Pegloticase for the Management of Tophaceous Gout (clinicaltrials.gov) -  Apr 30, 2024   
    P1,  N=9, Enrolling by invitation, 
    Trial primary completion date: Oct 2023 --> May 2023 Not yet recruiting --> Enrolling by invitation
  • ||||||||||  Krystexxa (pegloticase) / Amgen
    ACHIEVEMENT OF "GOUT REMISSION" DURING INTENSIVE URATE-LOWERING OVER 52 WEEKS OF PEGLOTICASE THERAPY (Poster Tour 5) -  Mar 29, 2024 - Abstract #EULAR2024EULAR_1846;    
    These data demonstrate that successful intensive SU-lowering with pegloticase and subsequent urate depletion[ 11,12 ] result in marked improvements in both gout signs/symptoms and patient QOL. Additionally, these data further demonstrate that many patients benefit from pegloticase treatment that is longer than 6 months.
  • ||||||||||  Krystexxa (pegloticase) / Amgen, Rituxan (rituximab) / Roche
    Resolution of Severe Tophi with Recombinant Uricase in A Kidney Transplant Recipient () -  Mar 23, 2024 - Abstract #NKFSCM2024NKF_SCM_955;    
    Recombinant uricase shows effectiveness in KTR with severe gout with significant tophi. Further clinical trials are warranted to evaluate the efficacy and safety of recombinant uricase in this high-risk population.
  • ||||||||||  Krystexxa (pegloticase) / Amgen
    PEGLOTICASE FOR TUMOR LYSIS SYNDROME (SUN-345; Exhibition Hall and Main Foyer) -  Mar 8, 2024 - Abstract #ISNWCN2024ISN_WCN_1891;    
    Pegloticase is extremely effective and safe in cancer patients with severe tumor lysis syndrome. None of the patients who received Pegloticase ended up needing dialysis, ICU transfer or prolonged hospitalization.
  • ||||||||||  Krystexxa (pegloticase) / Amgen
    Burden of Disease in Patients With Uncontrolled Gout in the USA () -  Mar 8, 2024 - Abstract #ISPOR2024ISPOR_2154;    
    None of the patients who received Pegloticase ended up needing dialysis, ICU transfer or prolonged hospitalization. This retrospective study identified patients considered to have uncontrolled gout (?3 flares within 18 months with accompanying treatment or ?1 pegloticase prescription(s) following gout diagnosis) between June 2011 and May 2020 from a US health plan claims database (IQVIA PharMetrics
  • ||||||||||  Krystexxa (pegloticase) / Amgen
    Evaluation of Real-World Treatment Patterns in Patients With Uncontrolled Gout in the USA () -  Mar 8, 2024 - Abstract #ISPOR2024ISPOR_2134;    
    This retrospective study identified patients considered to have uncontrolled gout (?3 flares within 18 months with accompanying treatment or ?1 pegloticase prescription(s) following gout diagnosis) between June 2011 and May 2020 from a US health plan claims database (IQVIA PharMetrics Patients received a median (range) of 2.0 (0.0
  • ||||||||||  Krystexxa (pegloticase) / Amgen
    Trial completion:  A Phase 4, Open-label Study of KRYSTEXXA (clinicaltrials.gov) -  Jan 31, 2024   
    P4,  N=50, Completed, 
    Patients received a median (range) of 2.0 (0.0 Active, not recruiting --> Completed
  • ||||||||||  Krystexxa (pegloticase) / Amgen
    Trial completion, Trial completion date, Trial primary completion date:  A Study Exploring Efficacy of Pegloticase in Subjects With Asymptomatic Hyperuricemia (clinicaltrials.gov) -  Dec 27, 2023   
    P1,  N=45, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Jun 2024 --> Jan 2023 | Trial primary completion date: Jun 2023 --> Jan 2023
  • ||||||||||  Krystexxa (pegloticase) / Amgen, Elitek (rasburicase) / Sanofi, PAT-101 / Pasithea
    Preclinical, Journal:  In vivo study of newly developed albumin-conjugated urate oxidase for gout treatment. (Pubmed Central) -  Dec 23, 2023   
    Recruiting --> Completed | Trial completion date: Jun 2024 --> Jan 2023 | Trial primary completion date: Jun 2023 --> Jan 2023 All results suggest that this rHA-conjugated AfUox, PAT101, can be provided as a reliable source of Uox for gout treatment.
  • ||||||||||  Omontys (peginesatide) / Affymax, Krystexxa (pegloticase) / Amgen
    Review, Journal:  A singlicate immunogenicity method to detect anti-polyethylene glycol antibodies: pre- and post-dose of PEGylated therapies. (Pubmed Central) -  Nov 22, 2023   
    Materials & The repetitive, linear PEG structure prevented the use of a bridging homogenous format, hence the requirement to use a solid phase extraction and acid dissociation assay coupled with the Meso Scale Discovery platform. Results & Using singlicate analysis, the method was validated to successfully detect APA pre- and postdose, with a crucial aspect of the method being the preparation of an appropriate negative control.
  • ||||||||||  Krystexxa (pegloticase) / Amgen, Kineret (anakinra) / SOBI
    Acute Pain Secondary to Debilitating Polyarticular Gout on the Inpatient Rehabilitation Unit: A Case Report () -  Nov 16, 2023 - Abstract #AAPMR2023AAPMR_490;    
    Consulting rheumatologists recommended treatment with anakinra, steroids, colchicine, and allopurinol, but deferred initiation of uricase enzymes. As physiatrists, patient advocacy is crucial in the management of complex patient diagnoses and systems such as interdisciplinary teams, hospitals, and insurance companies.
  • ||||||||||  Krystexxa (pegloticase) / Amgen, Kineret (anakinra) / SOBI, Ilaris (canakinumab) / Novartis
    Journal:  Drugs for gout. (Pubmed Central) -  Nov 3, 2023   
    This review will include their No abstract available
  • ||||||||||  Krystexxa (pegloticase) / Amgen
    Trial completion date, Trial primary completion date:  Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome (clinicaltrials.gov) -  Oct 30, 2023   
    P4,  N=10, Recruiting, 
    No abstract available Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
  • ||||||||||  Krystexxa (pegloticase) / Amgen, Kineret (anakinra) / SOBI, Ilaris (canakinumab) / Novartis
    Journal:  Comparison table: Some drugs for gout. (Pubmed Central) -  Oct 24, 2023   
    Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 No abstract available
  • ||||||||||  Krystexxa (pegloticase) / Amgen
    Real-world Trends in the Use of Immunomodulation as Co-therapy to Pegloticase: Claims-based Findings Since 2016 (Poster Hall; in person) -  Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3239;    
    Compelling real-world 5, 11 and clinical trial 9 efficacy/safety data has led to wide-spread awareness and adoption of IMM co-administration with pegloticase, often a last-hope therapy for patients suffering from uncontrolled gout. In the last part of 2022, over 70% of patients beginning pegloticase were co-administered IMM, with the majority of these patients receiving MTX.
  • ||||||||||  Krystexxa (pegloticase) / Amgen
    Evaluation of Outcomes Following Discontinuation of Pegloticase Therapy (Poster Hall; in person) -  Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3219;    
    An important minority of patients fail to receive any ULT after cessation of pegloticase. Additionally, many patients who were able to restart restarting pegloticase after a prolonged gap in therapy achieved had its expected resulting SU-lowering effect with therapy even after a gap in therapy, although the context for the interruption needs to be further explored.
  • ||||||||||  Krystexxa (pegloticase) / Horizon Therapeutics
    Journal:  WHEN TOPHACEOUS GOUT INVOLVES MULTIPLE ORGANS: CHALLENGES AND SOLUTIONS. (Pubmed Central) -  Aug 21, 2023   
    Despite an aggressive intervention, hypercalcemia might not resolve spontaneously, as long as an ongoing inflammatory process secondary to gouty tophi is taking place. Herein, we present the case of a 62-year-old man with a long history of gouty tophi who presented for back pain and was found to have spinal cord involvement with PTH-independent hypercalcemia which only resolved with pegloticase therapy.
  • ||||||||||  Krystexxa (pegloticase) / Horizon Therapeutics
    Journal:  Pegloticase in Uncontrolled Gout: The Infusion Nurse Perspective. (Pubmed Central) -  Jul 9, 2023   
    This educational overview includes a model patient case for pegloticase monotherapy, as well as one for pegloticase with immunomodulation and a step-by-step checklist for infusion nurses to refer to throughout the pegloticase infusion process. A video abstract is available for this article at http://links.lww.com/JIN/A105.
  • ||||||||||  Krystexxa (pegloticase) / Amgen
    Enrollment closed, Trial completion date, Trial primary completion date:  A Phase 4, Open-label Study of KRYSTEXXA (clinicaltrials.gov) -  Jun 28, 2023   
    P4,  N=40, Active, not recruiting, 
    Tophi resolution continued to increase through week 52, suggesting continued therapeutic benefit beyond month 6 for a favorable treatment effect. Recruiting --> Active, not recruiting | Trial completion date: Oct 2023 --> Mar 2024 | Trial primary completion date: Aug 2023 --> Nov 2023